Abiogen Pharma, a company in the field of osteoarticular and bone metabolism diseases, completed the acquisition of a 97.09% stake in EffRx Pharmaceuticals, a company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies. Financial terms were not disclosed. "Besides strengthening our position in Italy, the acquisition of a majority interest in EffRx is in line with our growth model, serves as a launching pad for our international expansion and confirms our mission and commitment to bone health and rare diseases," Massimo Di Martino, Abiogen Pharma Chairman and CEO.